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Loss of von Hippel–Lindau protein (pVHL) is known to contribute to the initiation and progression
of tumours associated with VHL disease as well as certain sporadic tumours including clear cell
renal cell carcinoma (ccRCC). The VHL gene was ﬁrst identiﬁed and cloned over 20 years ago and
our understanding of its functions and effects has signiﬁcantly increased since then. The best-
known function of pVHL is its role in promoting the degradation of hypoxia-inducible factor a sub-
unit (HIFa) as part of an E3 ubiquitin ligase complex. HIF stabilisation and transcriptional activation
are also associated with various epigenetic alterations, indicating a potential role for VHL loss with
changes in the epigenome. This review will highlight current knowledge regarding pVHL as well as
discuss potentially novel roles of pVHL and how these may impact on cancer progression.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. von Hippel–Lindau (VHL) disease and gene
The ﬁrst indication of a tumour suppressor role for von Hippel–
Lindau (VHL) gene was the segregation of the mutant or loss of VHL
allele in kindreds with VHL disease. The disease was ﬁrst described
in the early 1900s and is named after Eugen von Hippel and Arvid
Lindau. von Hippel described a family with highly vascularised tu-
mours of the retina [1], whilst Lindau reported that these retinal
tumours commonly occurred alongside lesions of the central ner-
vous system [2]. The disease is now known to be a hereditary can-
cer syndrome that affects approximately 1 in 35,000 individuals.
Patients with VHL disease are at a high risk of developing benign
tumours most commonly found in the central nervous system
(haemangioblastoma), retina (angioma) and adrenal glands (phae-
ochromocytoma), as well as malignant tumours of the kidney
(clear-cell renal cell carcinoma; ccRCC). Although less frequent, a
variety of other benign tumours are also associated with the dis-
ease including tumours of the pancreas, inner ear and bilateral
papillary cystadenoma of the epidydimus in men or broad liga-
ment in females. Despite a wide range of pathological outcomes,
ccRCC is the most frequent cause of morbidity and mortality
amongst these patients.The disease is a result of germline mutations of VHL. Patients
are heterozygotes for VHLwith one wild-type and one defective al-
lele. Somatic inactivation of the second functional allele in suscep-
tible cells, and therefore loss of VHL function, leads to pathological
features of disease. VHL can be described as a classic tumour sup-
pressor gene as this outcome is in line with Knudson’s two hit
model of tumourgenesis, whereby tumour suppressors are reces-
sive at the genetic level and require somatic inactivation of the
remaining wild-type allele to achieve tumourgenesis [3].
2. VHL and sporadic cancer
While VHL is widely expressed in human tissue, its loss is not
exclusive to VHL disease. Certain sporadic cancers are strongly
associated with VHL mutation [4]. Biallelic inactivation of VHL,
due to mutation, loss or hypermethylation, is the most frequent ge-
netic mutation in sporadic ccRCC. ccRCC is the most common form
of kidney cancer, accounting for more than 70% of all RCC cases and
is often characterised by loss of chromosome 3p events [5]. The
prevalence of mutated VHL is study dependent, but it is estimated
that between 60–80% of sporadic ccRCC display VHL mutations [6–
8]. Thus, the majority of sporadic and hereditary (VHL disease-
associated) ccRCC lacks functional VHL due to loss or mutation of
the VHL gene. VHL loss is also associated with sporadic cerebellar
haemangioblastomas with prevalence between 25–50% [9,10].
VHL/ mice die in utero due to defective placental dysgenesis
[11], but targeted cell speciﬁc suppression of VHL is possible.
C.M. Robinson, M. Ohh / FEBS Letters 588 (2014) 2704–2711 2705In liver cells of mice, VHL suppression forms benign tumours that
are highly vascular in nature [12], while intriguingly targeted
VHL inactivation in renal proximal tubule epithelial cells and pan-
creatic endocrine cells results in a polycystic, pre-cancerous,
pathology in murine models [13,14]. In further support of its role
as a tumour suppressor gene, reintroduction of wild-type VHL into
VHL/ ccRCC cell lines prevents RCC cells from forming tumours in
nude mice [15].3. VHL protein (pVHL)
Located on the short arm of chromosome 3 (3p25-p26), the VHL
tumour suppressor gene was ﬁrst identiﬁed and cloned in 1993
[16]. The gene, which contains 3 exons, encodes a protein of 213
amino acid residues, speciﬁcally known as pVHL30. A second
wild-type isoform of 160 amino acid residues is also expressed in
human cells. pVHL19 arises from alternate translation initiation at
a second AUG codon (codon 54) within the VHL open reading
frame [17]. Both forms are known to display tumour suppressor
abilities. Reintroduction of RCC cells with either pVHL19 or pVHL30
inhibits tumour development in mouse xenograft models of the
disease [18]. Although both are expressed in human cells, pVHL19
is often the more prominent form in human tissue. Interestingly
VHL isoforms are also located in different compartments of the cell.
While VHL19 is equally distributed in the nucleus and cytoplasm,
VHL30 is found predominantly in the cytoplasm [17], suggesting
that under certain circumstances they display distinct roles. How-
ever, for the remainder of this review, unless otherwise stated,
both protein forms of VHL will be referred to as pVHL.4. pVHL functions
pVHL displays no enzymatic activity, but it is known to have
multiple binding partners. The protein comprises of an a and b
subunit. The a-domain serves as a binding site, whereas the b-do-
main plays important roles in substrate recognition. Investigations
into the binding partners of the protein reveal its vast array of
functions, many of which are relevant to its role as a tumour sup-
pressor protein. In addition, categorising VHL patients based on
disease outcome supports the notion that the tumour suppressor
roles of pVHL are diverse. Speciﬁc mutations place patients at a
higher risk of developing speciﬁc tumours. Patients with type 1
VHL disease display haemangioblastoma with a low risk of phaeo-
chromocytoma and ccRCC while type 2 patients, who also display
haemangioblastoma, have a high risk of developing phaeochromo-
cytoma. Type 2 is further subdivided into 2A (low risk of ccRCC), 2B
(high risk of ccRCC) and 2C who develop phaeochromocytoma
only. Taking these observations into account, research to date has
led to multiple discoveries about the precise functions of pVHL. It
can therefore be described as an adapter protein with both post-
translational as well as transcriptional effects.
Ubiquitylation represents an efﬁcient mechanism of tagging
proteins for degradation by the 26S proteasome. Ubiquitylation
of proteins is accomplished by the actions of a common ubiqui-
tin-activating enzyme (E1), an ubiquitin-conjugating enzyme (E2)
and an ubiquitin-ligating enzyme (E3 ligase). VHL forms a multi-
protein complex with elongins B and C, cullin 2 and Rbx-1 [19–
21]. This complex is structurally similar to the yeast multicomplex,
SCF (Skp1/Cdc53/F-box protein). Like the SCF complex, the ECV
(elongin/culin/VHL) complex displays E3 ubiquitin ligase activity,
which acts to polyubiquitylate protein substrates. Within this com-
plex, pVHL acts as a substrate recognition subunit [22]. The most
extensively studied and arguably most important protein target
of pVHL-mediated ubiquitylation is the hypoxia-inducible factor
(HIF) family of transcription factors, which will be discussed inmore detail in the following sections. However, other protein tar-
gets of the ECV have also been identiﬁed. These include certain iso-
forms of protein kinase C (PKC) [23], proposed to be of particular
importance in the regulation of c-Jun dependent apoptosis of neu-
rons that are potential precursors of phaechromocytoma [24]. The
ECV also targets the hyperphosphorylated form of Rpb1, a subunit
of RNA polymerase II, which is activated during UV radiation and
associated with stress-induced transcription [25].
Not all proteins that pVHL binds to results in polyubiquityla-
tion, indeed certain VHL mutations associated with cancer patho-
genesis are known to display normal ubiquitylation function,
including ubiquitylation of HIF. For example type 2C pVHL mutants
appear to retain the ability to polyubiquitylate HIF, but still have a
heightened likelihood of developing phaeochromocytoma [26].
Therefore, mutations such as these are likely to be promoting can-
cer progression independent of the VHL/HIF axis and the ECV com-
plex. In support of this investigations into alternate functions of
pVHL provide a diverse array of roles for this protein. pVHL assists
in regulation of the extracellular matrix (ECM), where its loss in
this context is proposed to promote angiogenesis by allowing ves-
sels to easier inﬁltrate tumours. pVHL and ﬁbronectin, a glycopro-
tein that interacts with integrin proteins to regulate the ECM, are
known to bind [27]. VHL/ cells secrete higher levels of ﬁbronectin
but the assembly of this ﬁbronectin as part of the ECM is disorgan-
ised. Loss of the pVHL-ﬁbronectin interaction is therefore associ-
ated with defective ECM formation. This is reversed upon
reintroduction of wild type pVHL [27]. More recently this has been
shown to be related to decreased RhoA GTPase signalling in VHL/
renal cancer cells [28]. pVHL also binds to collagen IV alpha 2
(COL4a2) [29]. In this context VHL loss is associated with a loss
of COL4a2 from the ECM [30], further deregulating the ECM archi-
tecture in the VHL/ tumour environment.
Microtubules are crucial for the maintenance of cell shape and
polarity, and in addition, form the mitotic spindle during cell divi-
sion. pVHL associates and binds to microtubules and inhibits their
depolymerisation [31]. In mammalian cells, Thoma et. al. demon-
strated that pVHL localises to the mitotic spindle and that loss of
this protein resulted in, amongst other things, chromosomal insta-
bility, a classic feature of cancer cells [32]. Microtubules are also
essential for cilia maintenance and therefore linked to this function
of pVHL is the role of the protein in cilia maintenance. Cilia are of
great importance in renal epithelial cells where primary cilia play
an important role in the development as well as maintaining the
integrity of nephrons. pVHL loss disrupts cilia formation in mouse
inner medullary collecting duct kidney cells where pVHL is needed
to direct the growth of microtubules toward the cell periphery, a
function that have been proven to be vital for cilia formation
[33]. Likewise, human VHL/ cells do not have cilia and reintro-
duction of pVHL into these cells results in cilia formation. Loss of
cilia in adult kidney cells due to pVHL dysfunction promotes the
development of renal cysts, indicative of a pre-cancerous
pathology.
VHL loss in ccRCC is also associated with genomic instability, a
prominent feature in multiple cancer cells. pVHL19 is found in the
nucleus [17], suggesting a nuclear relevant role for this isoform.
Recently functions for pVHL in the DNA damage response have
been reported. Upon DNA damage, VHL/ cells display attenuated
apoptosis or abnormal cell-cycle arrest, but when pVHL is restored
this response is normal [34]. Roe et. al. reported that pVHL desta-
bilises Skp2 protein, an integral component of the Skp, Cullin,
F-box-containing complex that promotes DNA synthesis in the S
phase [35]. The transcription factor E2F1 is also up-regulated as
part of the DNA damage response. Wei et. al. reported a feedback
loop wherein pVHL regulates E2F1 activity which in turn regulates
pVHL expression [36]. Recently, a possible physiologic role
for pVHL in the DNA damage response was revealed whereby
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redistribution and ubiquitylation of pVHL upon induction of
double-stranded DNA breaks. VHL loss or mutation in this system
signiﬁcantly attenuated the DNA damage response resulting in
increased accumulation of unrepaired DNA breaks [37].
pVHL is also proposed to be involved in modulating apoptotic
regulators including the tumour suppressors p53 and nuclear fac-
tor NF-jB and the transcription factor E2F1. Under normal circum-
stances, p53 functions to promote cell cycle arrest and apoptosis in
response to DNA damage as well as other stimuli. Roberts et. al.
demonstrated that in ccRCC, HIF2a expression subsequent to
VHL loss promotes Hdm2, an important mediator of p53 suppres-
sion [38], providing a potential mechanism of mutated VHL medi-
ated survival. Similarly pVHL modulates NF-jB. pVHL loss results
in increased NF-jB activity, which acts to promote oncogenesis
via activation of anti-apoptotic pathways as well as proliferative
pathways. Yang et. al. demonstrated that under normal circum-
stances pVHL that is bound to casein kinase 2 promotes the phos-
phorylation of Card9. Phosphorylated Card9 is an NF-jB agonist,
whereby lack of phosphorylated Card9 (as is the case with pVHL
loss) leads to increased NF-jB activity [39]. In further support of
this mechanism, suppressing Card9 in ccRCC cells lacking function
pVHL resulted in normal NF-jB activity [39]. Other roles for pVHL
with relevance to cell proliferation have been suggested by Wang
et. al. whom recently demonstrated that pVHL interacts with the
androgen receptor, inhibiting transcriptional activity of the recep-
tor that was linked to suppression of androgen-induced cell prolif-
eration. Intriguingly pVHL did not affect receptor turnover [40].
Interestingly, not all VHL mutations lead to cancer indicating
the multifaceted nature of this protein. A third group of patients
with VHL mutations are classiﬁed as having type 3 disease. Pa-
tients with type 3 disease do not have increased propensity for
cancer, but develop Chuvash polycythemia, a non-cancerous con-
dition of erythrocytosis. Chuvash polycythemia was ﬁrst identiﬁed
in the Chuvash population in Russia [41] and although the muta-
tions and disease are rare, they have since been found in patients
elsewhere. The main VHL mutation identiﬁed in Chuvash polycy-
themia is R200W and is distinguishable by overproduction of HIF
independent of tumour formation [42]. In addition, VHL-associated
Chuvash polycythemia cells exhibit elevated levels of phosphory-
lated JAK2, leading to increased JAK2-STAT5 signalling, which
likely accounts for the hypersensitivity of erythroid progenitor
cells to erythropoietin. JAK2 stabilisation may be due to the atten-
uation of SOCS1 mediated targeting of phosphorylated JAK2 in the
presence of mutated VHL [43].5. The VHL/HIF axis
Despite a growing knowledge of the various functions of VHL,
the most extensively characterised E3 ubiquitin ligase function of
pVHL to date, and arguably its most important, is its regulation
of the a-subunit of the HIF family of transcription factors [44–
46]. Current evidence overwhelmingly suggests that HIF stabilisa-
tion as a consequence of VHL loss or mutation is an important
oncogenic mechanism in VHL disease as well as sporadic ccRCC
and haemangioblastomas [4].
HIFs are basic helix–loop–helix–PAS domain proteins of which
there are three HIFa members (HIF1-3a) expressed in mammalian
cells along with the constitutively expressed HIF1b (also called aryl
hydrocarbon receptor nuclear translocator; ARNT). The HIFa and b
subunits contain the same basic subunits, a bHLH domain for DNA
binding, a Per-ARNT-Sim (PAS) involved in dimerization and a c-
terminus that facilitates binding with other regulatory proteins
(C-terminal transactivation domain; CAD). Under adequate oxygen
tension, HIFa subunits are expressed but the protein is rapidlyhydroxylated at two conserved proline residues by a family of oxy-
gen dependent enzymes called the prolyl hydroxylases (PHDs or
EGLNs) [47]. The PHDs, of which there are 4 expressed in mamma-
lian cells (PHD1-4), add an –OH group to proline 402 and proline
564 of the HIFa subunit [46,48]. Only hydroxylated HIFa is recog-
nised and bound via the b-domain of pVHL as part of the ECV com-
plex. pVHL E3 ligase ubiquitylates HIFa via physical interaction
with the core of the HIFa oxygen-dependent degradation domain
(ODD). Polyubiquitylation of HIFa results in rapid degradation by
the 26S proteasome such that HIFa is negligibly detectable in
normoxic cells (Fig. 1). In the majority of circumstances where
VHL is mutated or lost, HIFa is no longer recognised by the ECV
and escapes degradation. Thus in VHL/ tumours, HIF isoforms
are constitutively stabilised.
However, it should be noted that various other factors also af-
fect the stabilisation and expression of HIF. The most important
of which is the availability of oxygen. Frequently tumours are
highly hypoxic due to hyperactive tumour growth with a lagging,
or inappropriately directed, blood vessel growth resulting in inad-
equate oxygen supply. Such environments mean that oxygen levels
in a given tumour are highly heterogeneous. Measurements as low
as 5 mmHg pO2, which corresponds to approximately 0.7% O2, have
been recorded in regions of tumours [49]. During such circum-
stances of compromised oxygen availability, or hypoxia, the
oxygen-dependent PHDs are inhibited. HIFa is no longer hydroxyl-
ated and therefore escapes ubiquitylation and degradation and is
stabilised in the cell. Thus, HIF stabilisation, as a consequence of
VHL inactivation or hypoxia, is an important event in a wide
variety of cancers.
6. HIF-mediated transcription
Once expressed in a cell HIFa dimerises with the constitutively
expressed HIFb and this complex translocates to the nucleus. In the
nucleus HIF recruits coactivators p300/CBP [50] and subsequently
binds to a consensus hypoxia-responsive element (HREs; 50-[A/
G]CGTG-30). HIF induced gene transcription is further controlled
by factor inhibiting HIF (FIH) during adequate oxygen availability.
Similar to the PHDs, the 2-oxoglutarate (2OG) and Fe(II)-depen-
dent dioxygenase, FIH acts to hydroxylate an asparaginyl (Asn) res-
idue of HIFa in the C terminal transactivation domain [51]. Such
hydroxylation acts to restrict transcriptional activation of HIF by
blocking the recruitment of p300/CBP. Therefore during periods
of oxygen limitation FIH no longer catalyses this reaction, resulting
in heightened HIF transcriptional binding and activation at hypoxia
responsive gene promoters or HIF binding sites.
HIF acts to up-regulate a variety of hypoxia responsive genes
that are involved in promoting an adaptive response to low oxygen
tension. Genomic analysis of direct HIF binding sites suggests that
HIF can directly target as many as 500 sites although exact num-
bers vary depending on the cell type interrogated [52,53]. Genes
directly affected by HIF binding include those that promote energy
metabolism (e.g. glucose transporter 1; GLUT1, phosphoglycerate
kinase; PKG, lactose dehydrogenase A; LDHA), genes that up-regu-
late new blood vessel growth/angiogenesis (e.g. vascular endothe-
lial growth factor; VEGFA), erythropoiesis (e.g. erythropoietin; EPO)
and cell survival (e.g. transforming growth factor-a; TGFa). To date
over 70 genes have been validated as direct HIF target genes [54],
although given more recent genome wide studies it is apparent
that the actual number may be signiﬁcantly higher.7. HIF stabilisation and cancer progression
Tumours associated with VHL disease as well as sporadic ccRCC
and haemangioblastoma display an erratic vascular network
Fig. 1. Regulation of HIF protein. (A) During situations of normal oxygen tension, normoxia, HIF isoforms are expressed. However HIFa becomes rapidly hydroxylated at two
proline residues by a family of oxygen and a-ketoglutarate dependent enzymes called the prolyl hydroxylases (PHDs). Hydroxylated HIFa is subsequently recognised by von
Hippel–Lindau (VHL) tumor suppressor protein as part of the ECV complex. This results in rapid polyubiquitylation and degradation by the 26S proteosome. (B) When oxygen
levels in a cell are decreased, in hypoxic situations, the PHDs are inhibited. This allows HIFa isoforms to dimerise with the constitutively expressed ARNT (also called HIFb).
This transcription factor translocates to the nucleus where it binds to hypoxia responsive elements (HREs) to initiate transcription of HIF responsive genes. These include
genes involved in promoting angiogenesis, cell metabolism and erythropoiesis. Similarly, when VHL is mutated/lost the ability of the ECV complex to recognise hydroxylated
HIF is lost, resulting in an increase in HIF expression as well as HIF mediated gene transcription.
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haemangioblastoma along with ccRCC and phaeochromocytomas
are characterised by increased production of EPO [56]. Such char-
acteristics can be largely attributed to the HIF dependent functions
of pVHL, which under normal circumstances would act to suppress
expression of such genes. Thus loss of VHL, or indeed hypoxia, acti-
vates a pathway that, amongst other functions, promotes angio-
genesis and cell survival, advantages utilised by cancer cells.
Otto Warburg ﬁrst observed, over 70 years ago, that cancer cells
metabolize glucose in a manner that is in contrast from that of cells
in normal tissues [57]. Now termed the Warburg effect, it is well
recognised that cancer cells utilise anaerobic metabolic pathways
to generate adenosine triphosphate (ATP) producing, as a conse-
quence, high levels of lactate. This occurs independent of oxygen
availability and is in contrast to normal cellular metabolism, which
in the presence of oxygen, metabolizes glucose to carbon dioxide
by oxidation of glycolytic pyruvate in the mitochondrial tricarbox-
ylic acid (TCA) cycle. Aerobic metabolism produces NADH, which
then fuels oxidative phosphorylation to maximise ATP production.
In contrast to anaerobic metabolism, this reaction results in mini-
mal synthesis of lactate. pVHL loss and subsequent HIF stabilisa-
tion play an important role in promoting such phenotypic
changes that characterise tumours. HIF mediated gene transcrip-
tion signiﬁcantly promotes anaerobic metabolism in a cell by acti-
vating genes such as GLUT1, LDHA and PKG, which promote glucose
uptake and oxygen independent metabolism.
In addition to the aforementioned functions, HIF stabilisation
as a consequence of VHL loss encourages other pro-oncogenicpathways including those involved in epithelial mesenchymal
transition [58,59] as well as invasion and metastasis [60]. Thus,
HIF stabilisation is a common occurrence in tumour biology and
is associated with an adverse prognosis [61]. Investigating the con-
tribution of HIFa to tumour initiation and progression continues to
be an area of active research, particularly understanding the exact
targets of both HIF1a and HIF2a. Despite multiple overlapping
transcriptional targets of HIF1a and 2a, research investigating
ccRCC suggests that gene targets unique to one or other isoform
may enable pro- or anti-oncogenic arms of the HIF pathway [62].
The strongest evidence for this has been highlighted in VHL associ-
ated ccRCC. Interestingly, arm level losses on chromosome 14q,
associated with loss of HIF1a, which originally was predicted to
drive more aggressive disease in fact is considered a protective
mechanism. One recent study demonstrated that patients with
ccRCC that lacked both VHL and HIF1a harboured signiﬁcantly
more aggressive tumours than patients that had VHL loss alone.
Patients with 14q deletion (HIF1a loss) had worse outcomes than
patients that retained HIF1a [63]. This is supported by various
in vitro and in vivo experiments. ccRCC cells and xenografts with
either HIF1a or HIF2a demonstrate different phenotypes. As ex-
pected HIF2a promotes growth, however, HIF1a results in de-
creased growth [64]. The transcriptional targets of HIF1a and 2a
provide insight into why this is the case. HIF2a mediates expres-
sion of pro-oncogeneic genes such as cyclin D1, VEGF and TGFa,
while HIF1a activates expression of pro-apoptotic genes such as
BNIP3 [65]. In further support of this theory, the expression and
behaviour of one HIF isoform appears to inﬂuence that of the other.
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vice versa, suggesting that these two transcription factors do not
necessarily work in unison [65]. Such contrasting properties have
led researchers to suggest that in ccRCC, HIF1a may have tumour
suppressor functions while HIF2a promotes disease progression
[62].
Given the importance of HIF in VHL disease, sporadic ccRCC and
phaeochromocytoma as well as its importance in multiple other
cancers when stabilised due to hypoxia, such observations have
highlighted the need to dissect the pVHL/HIF axis in order to truly
understand what promotes and controls HIF1a and HIF2a medi-
ated transcription. One exciting new avenue of research investi-
gates the role of chromatin remodelling and epigenetic
modiﬁcation in mediating this response.
8. Chromatin remodelling and gene transcription
As is the case with any transcription factor, in order to bind, the
DNA must be arranged in a manner that is conducive to allow easy
access to speciﬁc sequences. This is determined by chromatin
structure, which is governed by a variety of factors. Included and
essential to these are epigenetic modiﬁcations that play a vital role
in regulating chromatin structure and thus controlling the accessi-
bility of proteins, including transcription factors to chromatin. Epi-
genetic modiﬁcations encompass a variety of alterations that
include DNA methylation and histone modiﬁcations (Fig. 2). Regu-
lating the extent of DNA methylation at cytosine residues or mod-
ifying histone tails deems transcription factor binding sites either
active (available for transcription) or inactive (unavailable for tran-
scription). Thus, the response of a cell to a given transcription fac-
tor can be signiﬁcantly inﬂuenced by the extent of transcriptionally
active or inactive loci available to it. In this context, one could
expect that epigenetic modiﬁcations would effect HIF mediated
transcription in a similar manner [66].
Investigations into the genetic mutations in ccRCC demonstrate
that in addition to VHL mutations, many of these tumours harbour
mutated genes that are involved in chromatin remodelling. TheseFig. 2. DNA methylation and histone modiﬁcations represent two important mechanis
where a CH3 group is added to the 5th carbon of the pyramidine ring, resulting in 5meth
methyltransferases (DNMTs; purple) of which there are three active forms found in mam
repressive chromatin, where methylated cytosines act as a binding platform for meth
modifying proteins (pink) resulting in a condensed chromatin structure. (B) The N-termin
mono-di- and tri-methylation as well as acetylation which are catalysed by histone methy
deacetylases remove these marks. Unlike histone acetylation that is associated with ac
dependent. For example H3K9me3 is associated with gene repression and a condensed
relaxed chromatin.include a component of the SWI/SNF chromatin remodelling com-
plex PBRM1 (encoding Polybromo 1) [67], the histone methyltrans-
ferase SETD2 and the histone demethylases UTX (KDM6A) and
JARID1C (KDM5C) [68,69]. Although the histone methyltransferase
and demethylase mutations are present in less than 15% of tu-
mours, PBRM1 mutations were found in 41% of the samples ana-
lysed making it the second most commonly mutated gene in
ccRCC after VHL [67–69]. Such modiﬁcations contribute possibly
to an epigenetic landscape that allows for the promotion of tumour
growth and cancer progression.
Interestingly the SWI/SNF complex, of which PBRM1 is a part,
appears to be necessary for mediating transcriptional responses
to hypoxia as well as directly promoting HIF1a expression [70].
Thus it is tempting to predict that a modiﬁed epigenetic proﬁle,
as is found in cancer cells, may act to promote more aggressive dis-
ease by in part inﬂuencing HIF mediated transcription, although
little is known about the precise effects of PBRM1 mutations or in-
deed any other chromatin remodelling mutations on HIF transcrip-
tion. Interestingly, what is known is that while epigenetic
modiﬁcations may help determine the extent of HIF mediated
transactivation in a given cell, HIF itself also directly targets genes
that are involved in chromatin remodelling [71].
9. Epigenetic involvement in the VHL/HIF axis
Comprehensive molecular proﬁling of over 400 ccRCC tumour
samples identiﬁed a globally hypomethylated proﬁle as a signature
of the disease [72]. McRonald et. al. investigated promoter speciﬁc
methylation in renal carcinoma patients and found signiﬁcant
changes in the DNA methylation levels compared to normal renal
tissue [73]. DNA methylation involves the addition of a methyl
group (CH3) to the 5th carbon of the cytosine ring, becoming 5
methylcytosine (5MeC). Classically associated with gene silencing,
the DNA methylation proﬁle is signiﬁcantly altered when a variety
of cell types including colorectal cancer cells [74], benign prostate
epithelial cells [75] and ﬁbroblasts [76] are grown in hypoxia.
The precise mechanism promoting such changes are less wellms of epigenetic regulation. (A) DNA methylation occurs at cytosine (C) residues,
ylcytosine (5MeC). This reaction is catalysed by a family of enzymes called the DNA
malian cells – DNMT1, DNMT3a and DNMT3b. DNA methylation is associated with
yl-domain binding proteins (blue) and subsequent recruitment of other histone
als of histone proteins (green) can undergo an array of modiﬁcations. These include
ltransferases and histone acetyltransferases respectively. Histone demethylases and
tive transcription and a relaxed chromatin structure, histone methylation is mark
chromatin structure, whereas H3K4me3 is associated with gene transcription and
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be HIF mediated responses given the fact the enzymes involved in
catalysing the DNA methylation reaction, the DNA methyltransfer-
ases (DNMTs), all contain putative HREs in their promoters, while
studies have demonstrated that they display altered expression in
response to hypoxia [77,78]. Adding an extra layer of complexity to
the interaction between HIF and DNA methylation is the fact that
DNA methylation modiﬁcations are reversible [79]. This is thought
to occur via twomechanisms. The ﬁrst is by passive demethylation,
which could occur as a consequence of reduced DNMT expression
or activity. The second is the more recent discovery that methyl-
ated cytosines residues can be actively demethylated by the activ-
ity of a group of dioxygenases called TETs (ten eleven
translocation) enzymes [80]. TETs catalyse the sequential hydrox-
ylation of 5MeC to 5-hydroxymethylcytosine (5hMeC), 5-formylcy-
tosine and 5-carboxylcytosine, leading to eventual DNA
demethylation. Interestingly, like the PHDs, TETs are a family of
Fe(II) and a-KG-dependent dioxygenases utilising molecular oxy-
gen to catalyse the DNA demethylating reaction. Given the signif-
icant changes in oxygen levels that occur in tumours, the activity
and expression of TETs, along with the levels of 5hMeC, likely con-
tribute to the dynamic DNA methylation proﬁle evident in cancers
[81]. Gene speciﬁc DNA methylation observations are in support of
a model whereby HIF mediated gene transcription is impacted by
levels of DNA methylation. Indeed within the consensus HRE se-
quence is a CpG site, which is known to be of functional impor-
tance in the regulation of both EPO and CA9. The HRE of both
have been reported as methylated in speciﬁc cell types where
HIF mediated transcription of such genes requires a methylation
free HRE [82,83]. In addition, Vanharanta et. al. demonstrated that
HIF mediated activation of cytohesin 1 interacting protein (CYTIP)
in VHL/ cells is enabled by loss of DNA methylation implicating
loss of DNAmethylation as a feature of an enhanced metastatic cell
phenotype when associated with VHL loss and HIF stabilisation
[84].
HIF relevant epigenetic modiﬁcations are not exclusive to DNA
methylation events. Perhaps the most convincing evidence of epi-
genetic involvement in the HIF mediated response is the fact that
many histone-modifying enzymes are direct HIF target genes. Res-
idues of histone tails can undergo a variety of modiﬁcations. These
include lysine residues that can become mono-, di- or tri- methyl-
ated, a reaction mediated by histone methyltransferases and re-
versed by histone demetylases. A signiﬁcant proportion of the
demethylases, speciﬁcally numerous enzymes that are JmjC do-
main-containing proteins, are direct HIF1a target genes [85,86].
Like the TETs and PHDs, these enzymes also require oxygen to per-
form their demethylase activity although their sensitivity to oxy-
gen levels remains to be further investigated. Interestingly there
have been reports that increased expression of such enzymes is
necessary to induce a complete HIF mediated response. Luo et. al.
reported that in breast cancer cells HIF1a interacts with the his-
tone demethylase jumonji domain containing protein 2C (JMJD2C).
JMJD2C acts to demethylate H3K9me3, a repressive histone mark.
The authors reported that this demethylation was required at the
promoters of some hypoxic responsive genes in order to elicit full
HIF mediated expression of these genes [87]. It is, however, para-
doxical that a histone demethylase that requires oxygen is seem-
ingly operating to enhance HIF-dependent transcription under
hypoxia.10. Conclusion
The role of VHL as a tumour suppressor protein is well docu-
mented. In the last two decades, researchers have made signiﬁcant
contributions to our understanding of the functions of this proteinand how its loss contributes to cancer pathogenesis. However, the
full extent of pVHL’s tumour suppressive contribution is not fully
understood and this remains an area of active research. To date,
anti-tumor functions suggest roles for pVHL in protein degrada-
tion, extracellular matix regulation, cilia formation, microtubule
maintenance, cellular proliferation as well as roles in the DNA
damage response. Indeed it is likely that there remains much to
learn about pVHL as even with current knowledge, understanding
is lacking as to how exactly certain mutations lead to heightened
likelihood of speciﬁc cancer forms. Despite the multifaceted nature
of pVHL, there is no doubt that central to its role as a tumor sup-
pressor is its regulation of HIFa subunits. HIF stabilisation signiﬁ-
cantly promotes a pro-oncogenic environment and dissecting the
precise mechanisms via which HIF performs such functions are
important in order to treat and understand cancer pathologies. Gi-
ven the fact that tumourigenesis classically manifests with both
genetic and epigenetic changes in malignant cells, it is tempting
to speculate that HIF activation contributes to the epigenetic land-
scape that has direct consequence to oncogenesis. This is of partic-
ular interest as it appears that in parallel the epigenome regulates
the HIF mediated response. Investigations to determine the extent
of which VHL loss or HIF stabilisation contributes to the epigenome
provides an exciting avenue of research and may offer a new per-
spective on the multifaceted roles of pVHL.
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